EffRx Pharma and Pharmaxis to commercialize Bronchitol in Switzerland

14 June 2019

Swiss drug developer EffRx Pharmaceuticals has entered into an exclusive license agreement with Australia’s Pharmaxis (ASX: PXS) for the registration and commercialization of Bronchitol (mannitol) for cystic fibrosis in Switzerland.

Under the terms of the agreement, EffRx will take responsibility for registering, obtaining pricing and reimbursement as well as commercializing Bronchitol in Switzerland. Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough, hence improving mucus clearance and lung function.

The product is inhaled as dry powder twice daily using a small handheld device and it is expected to be available on the Swiss market by 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK